XML 79 R62.htm IDEA: XBRL DOCUMENT
v3.22.1

Equity (Details) |  |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 30, 2021 $ / shares shares | Jul. 08, 2020 | May 03, 2019 | Feb. 08, 2019 $ / shares shares | Oct. 01, 2016 | May 06, 2016 | Feb. 08, 2016 shares | Nov. 30, 2021 USD ($) $ / shares shares | Aug. 31, 2021 USD ($) shares | Jul. 31, 2021 USD ($) shares | Nov. 21, 2020 USD ($) shares | Nov. 19, 2020 $ / shares shares | Sep. 30, 2019 USD ($) shares | Aug. 31, 2019 USD ($) $ / shares | Feb. 28, 2017 | Aug. 26, 2016 | Feb. 17, 2016 shares | Mar. 31, 2022 USD ($) $ / shares shares | Mar. 31, 2021 USD ($) | Dec. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2020 USD ($) $ / shares shares | Jan. 31, 2022 shares | Aug. 05, 2021 | Jun. 29, 2021 $ / shares shares | May 17, 2021 $ / shares | Mar. 12, 2020 $ / shares shares | Dec. 31, 2019 shares | May 09, 2018 $ / shares | Sep. 25, 2017 USD ($) | Mar. 21, 2016 $ / shares shares
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of common shares issued and outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.50% |  |  |  |  |  |  |  |  |  |
Common stock, par value (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.001 |  | $ 0.001 | $ 0.001 |  |  |  |  |  |  |  |  | $ 0.001
Ordinary shares authorized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 360,000,000
Agreement, description |  |  |  |  |  | the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company’s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. |  |  |  |  |  |  |  |  | the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company’s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company’s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit). | the Company issued 1,468,750 shares (“Shares”) of the Company’s Common Stock, par value $0.001 (the “Offering”) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the “SPA”). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares, shares |  |  |  |  |  |  |  |  |  | 1,111,112 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Financial amendment, description |  |  | the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (“FINRA”). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company’s common stock were exchanged for 17,693,625 shares of the Company’s Common Stock. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting service, description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Pursuant to the agreements, the Company issued 644,972 shares of the Company’s common stock for the consulting service from July 2019 to July 2024 for the service fee of $4,514,800 in aggregate, and recorded as stock subscription receivable. |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30,307,329 |  | 28,926,322 | 24,420,526 |  |  | 50,000 |  |  | 644,972 |  |  |
Consulting fees (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,514,800 |  | $ 4,514,800 |  |  |  |  |  |  |  |  |  |
Stock subscription receivable (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,031,660 |  | 2,257,400 | $ 3,160,360 |  |  |  |  |  |  |  |  |
Due to related parties consideration (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,872,340 |  |  |  |  |  | $ 2,693,548 | $ 1,717,051 |  |  |  |  |  |  |  |  |
Common stock price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7 |  |  |  |  |  |  |  |  |  |  | $ 2.25 |  |  |  |  |
Common stock, authorized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000,000 |  | 100,000,000 | 100,000,000 |  |  |  |  |  |  |  |  |
Shares per price (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5 |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,306,007 |  |  |  |  |  |  |  |
Warrant issued |  |  |  |  |  |  |  |  |  |  |  | 200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  | $ 2.25 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant term |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,384,615 |  |  |  |  |  |  |  |  |
Aggregate common stock shares |  |  |  |  |  |  |  | 673,605 |  |  |  |  |  |  |  |  |  | 915,856 |  | 915,856 |  |  |  |  |  |  |  |  |  |
Convertible promissory note value (in Dollars) | $ |  |  |  |  |  |  |  |  |  | $ 2,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of public offering |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | the Company closed its public offering (the “Public Offering”) of 1,100,000 units (the “Units”), with each Unit consisting of one share of the Company’s common stock, one Series A warrant (the “Series A Warrants”) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the “Series B Warrants,” and together with the Series A Warrants, the “Public Warrants”) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the “SEC”) on April 8, 2021 (as amended, the “Original Registration Statement”), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the “S-1MEF,” together with the Original Registration Statement, the “Registration Statement”). The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000. |  |  |  |  |  |  |
Issuance of common stock for debt (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 40,448 | $ 11,119,452 | $ 7,615,331 |  |  |  |  |  |  |  |  |
Gross proceeds from exercise of warrants (in Dollars) | $ |  |  |  |  |  |  |  | $ 4,244,452 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting agreement desciption | In November 2021, the Company entered into consulting agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted $1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant date. These shares have been issued during the year ended December 31, 2021. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | In November 2021, the Company entered into consulting agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted $1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant date. These shares have been issued during the year ended December 31, 2021. In January 2022, the Company agreed to pay the deferred service fees related to Public Offering amounted $4,296,763 by issuing 1,306,007 shares of unrestricted common shares, valued at $3.29 per share on the grant date. These shares have been issued as of March 31, 2022. |  |  |  |  |  |  |  |  |  |  |  |
Common shares, issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 75,000 |  |  |  |  |  |  |  |  |  |  |  |
Consulting and advisory services amount (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 169,500 |  |  |  |  |  |  |  |  |  |  |  |
Consulting and advisory services value per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2.26 |  |  |  |  |  |  |  |  |  |  |  |
Number of investors (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2 |  |
2016 Equity Incentive Plan [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 157,050 |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued pre-stock split |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Private Placement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregated capital contributions (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,615,331 |  |  |  |  |  |  |  |  |
Number of investors |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45 |  |  |  |  |  |  |  |  |
Purchase price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2.25 |  |  |  |  |  |  |  |  |
Number of investors (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2.25 |  |  |  |  |  |  |  |  |
IPO [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued to professional investors |  |  |  |  |  |  |  |  | 2,354,145 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock for debt (in Dollars) | $ |  |  |  |  |  |  |  |  | $ 6,875,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Legal fees (in Dollars) | $ |  |  |  |  |  |  |  |  | $ 850,429 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Series A Warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants exercised | 673,405 |  |  |  |  |  |  | 673,405 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants exercise price (in Dollars per share) | $ / shares | $ 6.3 |  |  |  |  |  |  | $ 6.3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Series B Warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants exercised | 200 |  |  |  |  |  |  | 200 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants exercise price (in Dollars per share) | $ / shares | $ 10 |  |  |  |  |  |  | $ 10 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Kameyama [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares, shares |  |  |  |  |  |  |  |  |  |  | 24,694 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Unpaid consulting fees (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  | $ 49,388 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Articles of Incorporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, par value (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.001 |  |  |  |
Articles of Incorporation [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, authorized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000 |  |  |  |
Articles of Incorporation [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, authorized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000,000 |  |  |  |
View Trade Securities Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60,000 |  |  |  |  |  |  |  |  |
Consulting fees (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 135,000 |  |  |  |  |  |  |  |  |
Placement agent agreement, description |  | Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restricted common shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,000 |  |  |  |  |  |
WallachBeth Capital LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,000 |  |  |  |  |  |
Consulting Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2.9 |  |  |  |  |  |  |  |  |
Unrestricted common shares | 316,934 |  |  |  |  |  |  | 316,934 |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |  |  |  |  |  |  |  |  |
Service fee amount (in Dollars) | $ |  |  |  |  |  |  |  | $ 1,478,590 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting Agreement [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Price per share (in Dollars per share) | $ / shares | $ 2.31 |  |  |  |  |  |  | $ 2.31 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Price per share (in Dollars per share) | $ / shares | $ 6.3 |  |  |  |  |  |  | $ 6.3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non Related Parties [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt conversion, description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | a.Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company’s common stock, and warrants to purchase 159,145 shares of the Company’s common stock. b. Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company’s common stock, and warrants to purchase 154,368 shares of the Company’s common stock. c. C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company’s common stock, and warrants to purchase 162,908 shares of the Company’s common stock. d. KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company’s common stock, and warrants to purchase 126,530 shares of the Company’s common stock. e. Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company’s common stock, and warrants to purchase 192,784 shares of the Company’s common stock. f.KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company’s common stock, and warrants to purchase 120,121 shares of the Company’s common stock. |  | a.Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company’s common stock, and warrants to purchase 159,145 shares of the Company’s common stock. b.Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company’s common stock, and warrants to purchase 154,368 shares of the Company’s common stock. c.C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company’s common stock, and warrants to purchase 162,908 shares of the Company’s common stock. d.KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company’s common stock, and warrants to purchase 126,530 shares of the Company’s common stock. e.Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company’s common stock, and warrants to purchase 192,784 shares of the Company’s common stock. f.KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company’s common stock, and warrants to purchase 120,121 shares of the Company’s common stock. |  |  |  |  |  |  |  |  |  |
BioLite [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares, shares |  |  |  | 74,997,546 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
BioKey [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  |  | 1,642,291 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares, shares |  |  |  | 29,561,231 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of investors (in Dollars per share) | $ / shares |  |  |  | $ 1.5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share Exchange Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  |  |  |  |  | 164,387,376 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued pre-stock split |  |  |  |  |  |  | 52,336,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share Exchange Agreement One [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  |  |  |  |  | 166,273,921 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued pre-stock split |  |  |  |  |  |  | 52,936,583 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share Exchange Agreement Two [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  |  |  |  |  | 163,159,952 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued pre-stock split |  |  |  |  |  |  | 51,945,225 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of common shares issued and outstanding |  |  |  |  |  |  | 79.70% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of issued share capital |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share Exchange Agreement Three [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  |  |  |  |  | 166,273,921 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued pre-stock split |  |  |  |  |  |  | 52,936,583 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share Exchange Agreement Four [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued post-stock split |  |  |  |  |  |  | 205,519,223 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued pre-stock split |  |  |  |  |  |  | 65,431,144 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares, shares |  |  |  |  |  |  |  |  |  |  |  |  | 428,571 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting agreement, description |  |  |  |  | On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (“Kameyama”) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s Common Stock at $1.00 per share for any amount exceeding $3,000. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Co-Dev Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Due to related parties (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |
Consulting Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 521,887 |  |  |  |  |  |  |  |  |
Consulting Agreement [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2 |  |  |  |  |  |  |  |  |
Consulting Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Price per share |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3.68 |  |  |  |  |  |  |  |  |

X
- Definition Aggregate Common Stock Shares. + References No definition available. + Details
Name: | abvc_AggregateCommonStockShares
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Agreement related description. + References No definition available. + Details
Name: | abvc_AgreementDescription
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Common stock issued after stock split. + References No definition available. + Details
Name: | abvc_CommonStockIssuedAfterStockSplit
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Common stock issued before stock split. + References No definition available. + Details
Name: | abvc_CommonStockIssuedBeforeStockSplit
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Common Stock, Shares Authorized + References No definition available. + Details
Name: | abvc_CommonStockShareAuthorized
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | abvc_ConsultingAgreementDesciption
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Consulting agreement description. + References No definition available. + Details
Name: | abvc_Consultingagreementdescription
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Convertible promissory note value. + References No definition available. + Details
Name: | abvc_ConvertiblePromissoryNoteValue
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Description of public offering . + References No definition available. + Details
Name: | abvc_DescriptionOfPublicOffering
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | abvc_EquityDetailsLineItems
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_FinancialAmendmentDescription
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Issuance of Common Stock. + References No definition available. + Details
Name: | abvc_IssuanceOfCommonStock
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | abvc_NumberOfInvestors
Namespace Prefix: | abvc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of issued share capital. + References No definition available. + Details
Name: | abvc_PercentageOfIssuedShareCapital
Namespace Prefix: | abvc_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | abvc_PlacementAgentAgreementDescription
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Restricted Common Shares. + References No definition available. + Details
Name: | abvc_RestrictedCommonShares
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Share price per share. + References No definition available. + Details
Name: | abvc_SharesIssuedPricePerShares
Namespace Prefix: | abvc_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_StockIssuedValue
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of stock subscription receivable. + References No definition available. + Details
Name: | abvc_StockSubscriptionReceivable
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | abvc_UnpaidConsultingFees
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_UnrestrictedCommonShares
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Warrant issued. + References No definition available. + Details
Name: | abvc_WarrantIssued
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Warrant term + References No definition available. + Details
Name: | abvc_WarrantTerm
Namespace Prefix: | abvc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The par value per share of security quoted in same currency as Trading currency. Example: '0.01'. + References No definition available. + Details
Name: | dei_EntityListingParValuePerShare
Namespace Prefix: | dei_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + References No definition available. + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockSharesAuthorized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586 + Details
Name: | us-gaap_DebtConversionConvertedInstrumentAmount1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The price per share of the conversion feature embedded in the debt instrument. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 5 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1B -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611 + Details
Name: | us-gaap_DebtInstrumentConvertibleConversionPrice1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Description of conversion terms for debt instrument. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644 + Details
Name: | us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of excess stock shares of an entity that have been sold or granted to shareholders. + References No definition available. + Details
Name: | us-gaap_ExcessStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Description of product support, consulting, business, or other advisory service agreements entered into between the managing member or general partner and the LLC or LP, affiliate of the managing member or general partner, or affiliate of the LLC or LP. Includes a description of the key provisions of such agreements and the amount of compensation for such services during the accounting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_IntercompanyAgreementsDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for shareholder services. Includes, but is not limited to, fee and expense for transfer and dividend disbursing agent. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 220 -Section 45 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268 + Details
Name: | us-gaap_InvestmentCompanyShareholderServiceFeeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_LegalFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromContributionsFromAffiliates
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow associated with the amount received from holders exercising their stock warrants. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromWarrantExercises
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support. + References No definition available. + Details
Name: | us-gaap_ProfessionalAndContractServicesExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07.2(a),(b),(c),(d)) -URI https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 220 -Section 45 -Paragraph 3 -Subparagraph (k) -URI https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268 + Details
Name: | us-gaap_ProfessionalFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Change in number of shares issued and outstanding as a result of capital structure change to a stock dividend, stock split or reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statements or the effective date of registration statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770 + Details
Name: | us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644 + Details
Name: | us-gaap_WarrantExercisePriceDecrease
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=abvc_SeriesAWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=abvc_SeriesBWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_KameyamaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_ArticlesOfIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_ViewTradeSecuritiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_WallachBethCapitalLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_ConsultingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_NonRelatedPartiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=abvc_BioLiteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=abvc_BioKeyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_CodevelopmentagreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_ConsultingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |